CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's InjectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1479 Isavuconazonium sulfate Wiki 0.50

Correlated MeSH Terms (10)

Name (Synonyms) Correlation
D001228 Aspergillosis NIH 1.00
D009091 Mucormycosis NIH 0.71
D055732 Pulmonary Aspergillosis NIH 0.71
D001229 Aspergillosis, Allergic Bronchopulmonary NIH 0.71
D020096 Zygomycosis NIH 0.71
D009181 Mycoses NIH 0.50
D003550 Cystic Fibrosis NIH 0.35
D005355 Fibrosis NIH 0.27
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Conducting an Initial Small, Controlled Clinical Trial to Assess for Therapeutic Vaccine Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients.

Conducting an initial small, controlled clinical trial to assess for therapeutic vaccine activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. Produce Antigen Presentation Memory to COVID-19 Specific Antigen. 4. Produce Trained Immunity to COVID-19 Specific Antigen. 5. Avoid Antibody-Dependent Enhancement to COVID-19 Virus.

NCT03305341 Covid19 Biological: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

Primary Outcomes

Description: Macrophage Migration Inhibitory Factor (MMIF), assessed by ELISA Sandwich Kit

Measure: Macrophage Migration Inhibitory Factor (MMIF)

Time: Duration at least 28 days

2 Follow NCT03305341 - Conducting an Initial Small, Controlled Clinical Trial to Assess for COVID-19 Therapeutic Vaccine Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients.

Conducting an initial small, controlled clinical trial to assess for COVID-19 therapeutic vaccine activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. Produce Antigen Presentation Memory to COVID-19 Specific Antigen. 4. Produce Trained Immunity to COVID-19 Specific Antigen. 5. Avoid Antibody-Dependent Enhancement to COVID-19 Virus.

NCT03348670 Covid19 Biological: COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

Primary Outcomes

Description: Each dose of Nucleocapsid-GM-CSF contains a minimum of 50 million autologous CD54+ cells activated with Nucleocapsid-GM-CSF, suspended in 250 mL of Lactated Ringer's Injection, USP. Intravenous Injection, IV After 60 hours Test Macrophage Migration Inhibitory Factor (MMIF) If Macrophage Migration Inhibitory Factor (MMIF) is positive (+) Successful trained immunity to COVID-19 specific antigen

Measure: Test Macrophage Migration Inhibitory Factor (MMIF)

Time: 28 days

No related HPO nodes (Using clinical trials)